Ignite Creation Date:
2025-12-17 @ 1:17 PM
Ignite Modification Date:
2025-12-23 @ 4:55 PM
Study NCT ID:
NCT06038461
Status:
RECRUITING
Last Update Posted:
2024-10-01
First Post:
2023-09-08
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-15
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09-15
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-08
First Submit QC Date:
None
Study First Post Date:
2023-09-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-28
Last Update Post Date:
2024-10-01
Last Update Post Date Type:
ACTUAL